Clinical and investigational considerations for the use of IGIV therapy

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 3, 2005, Pages

  Ballow, Mark ^a,b  

^a Division of Allergy/Immunology and Pediatric Rheumatology   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Concentration; Contamination; Control, quality; Drug use; Excipients; Formulations; Globulin immune; Injections; Manufacturing; Mechanism of action; Osmolarity; Serums; Sodium chloride; Stabilizers; Sugars; Toxicity; Volume

Indexed keywords

COMPLEMENT; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CHEMICAL COMPOSITION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; OSMOLALITY; PRIORITY JOURNAL; TOXIC EPIDERMAL NECROLYSIS;

EID: 23844475792     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050283     Document Type: Conference Paper

References (46)

1. Kazatchkine MD, Kaveri S. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345:747-55.
2. Lacroix-Desmazes S, Kaveri SV, Mouthon L et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods. 1998; 216:117-37.
3. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999; 22:1479-97.
4. Ochs HD, Ament ME, Davis SD. Giardiasis with malabsorption in X-linked agammaglobulinemia. N Engl J Med. 1972; 287:341-2.
5. Saulsbury FT, Winkelstein JA, Yolken RH. Chronic rotavirus infection in immunodeficiency. J Pediatr. 1980; 97:61-5.
6. Roifman CM, Rao CP, Lederman HM et al. Increased susceptibility to mycoplasma infection in patients with hypogammaglobulinemia. Am J Med. 1986; 80:590-4.
7. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999; 92:34-48.
8. Roifman CM, Levinson H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinemia and chronic lung disease. Lancet. 1987; 1:1075-7.
9. Quartier P, Debre M, De Blic J et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999; 134:589-96.
10. Eijkhout HW, van der Meer JWM, Kallenberg CGM et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann Intern Med. 2001; 135:165-74.
11. Chapel H, Griffiths H, Brennan V et al. Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy. Immunol Invest. 1991; 20:187-91.
12. Griffiths H, Lea J, Bunch C et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1992; 89:374-7.
13. Chapel HM, Lee M. The use of intravenous immune globulin in multiple myeloma. Clin Exp Immunol. 1994; 97(Suppl 1):21-4.
14. Hargreaves RM, Lea JR, Griffiths H et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol. 1995; 48:260-6.
15. Molica S, Musto P, Chiurazzi F et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (FVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996; 81:121-6.
16. Crow ME. Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients. Am J Health-Syst Pharm. 1995; 52:803-11.
17. Olopoenia L, Young M, White D et al. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc. 1997; 89:543-7.
18. Sullivan KM. Immunoglobulin therapy in bone marrow transplantation. Am J Med. 1987; 83:34-45.
19. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990; 323:705-12.
20. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981; 1(8232):1228-31.
21. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88:36-40.
22. Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology. 1997; 48(Suppl 1):64-9.
23. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997; 349:225-30.
24. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med. 1995; 88:493-502.
25. Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology. 1998; 51:16-21.
26. Bowers W. Cells involved in immune responses. In: Hunt R. Microbiology and Immunology On-Line. http://www.med. sc.edu:85/bowers/immune%20cells.htm. Accessed 2005 May 26.
27. Gelfand EW. Antibody-directed therapy: past, present, and future. J Allergy Clin Immunol. 2001; 108(4 Suppl):S111-6.
28. Daëron M. Fc receptor biology. Annu Rev Immunol. 1997; 15:203-34.
29. Clarkson SB, Bussel JB, Kimberly RP et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med. 1986; 314:1236-9.
30. Debré M, Bonnet MC, Fridman WH et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993; 342:945-9.
31. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001; 291:484-6.
32. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997; 126:721-30.
33. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315:341-7.
34. Kaul R, McGeer A, Norrby-Teglund A et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999; 28:800-7.
35. Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P et al. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. Biodrugs. 2002; 15:47-55.
36. Leung DY, Cotran RS, Kurt-Jones E et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 1989; 2:1298-1302.
37. Sharief MK, Ingram DA, Swash M et al. I.V. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology. 1999; 52:1833-8.
38. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994; 94:1729-35.
39. Leung DY. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol. 1996; 104(Suppl 1):49-54.
40. Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol. 2001; 108(4 Suppl):S107-10.
41. Sultan Y, Kazatchkine MD, Maisonneuve P et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984; 2:765-8.
42. Kaveri SV, Dietrich G, Kazatchkine MD. Can intravenous immunoglobulin treatment regulate autoimmune responses? Semin Hematol. 1992; 29(3 Suppl 2):64-71.
43. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest. 1990; 85:620-5.
44. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999; 340:227-8.
45. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health-Syst Pharm. 2005; 62(Suppl 3):S5-11.
46. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998; 282:490-3.